MIAMI, June 18, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer's disease has been accepted for Poster Presentation at the 2026 Alzheimer's Association International Conference® (AAIC®), to be held July 12-15, 2026 in London, United Kingdom and online. Poster Presentation (Exhibit Hall) Date: Monday, July 13, 2026 Time: 7:30am – 4:15pm BST Session: In-Person Posters Tuesday; Drug Development: Human Topic: Laromestrocel in Mild Alzheimer's Disease: Additional Phase 2a Clinical Data Analysis Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer's disease and provided evidence-based support for further clinical development, were published in the peer-reviewed journal Nature Medicine in March 2025.
